Michael Bromberg, MD, PhD, Chief of the Section of Hematology at Temple University Hospital, discussed with HealthCentral two newly approved gene therapies for patients with the genetic blood disorder transfusion-dependent beta thalassemia.
Michael Bromberg, MD, PhD, Chief of the Section of Hematology at Temple University Hospital, discussed with HealthCentral two newly approved gene therapies for patients with the genetic blood disorder transfusion-dependent beta thalassemia.
Researchers have developed a new treatment program for type 2 diabetes, called GEM, which offers an individualized approach that teases out the few foods that spike blood sugar the most so patients can focus on reducing those foods without dieting.
Read MoreThe Hepatitis C Allies of Philadelphia hosted an evening celebrating Hepatitis Awareness Month.
Read More